Amisulpride in the Treatment of Schizophrenia

被引:0
|
作者
Ustohal, Libor [1 ,2 ]
机构
[1] CEITEC MU, Brno, Czech Republic
[2] LF MU & FN Brno, Psychiat Klin, Brno 62500, Czech Republic
关键词
amisulpride; schizophrenia; positive symptoms; negative symptoms; CLOZAPINE-INDUCED HYPERSALIVATION; CONTROLLED-TRIAL; DOUBLE-BLIND; ANTIPSYCHOTICS; IMPROVEMENT; OLANZAPINE; AUGMENTATION; METAANALYSIS; MANAGEMENT; RECEPTORS;
D O I
暂无
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Amisulpride is a second generation D2 and D3 receptor blocking antipsychotic agent. It has so called biphasic affect - low doses increase and higher doses decrease dopaminergic neurotransmission. It has proven efficacy in the treatment of positive as well as negative symptoms of schizophrenia and, it is assumed that it also impacts on affective (depressive) symptoms and cognitive dysfunction. Amisulpride is effective as monotherapy although some evidence also exists of its efficacy when used in combinations, namely in combination with clozapine and, alternatively, olanzapine. It has only a few contraindications and, due to relatively low number of side-effects, is well-tolerated.
引用
收藏
页码:706 / 708
页数:3
相关论文
共 50 条
  • [31] White matter connectivity related to amisulpride treatment response in patients with schizophrenia
    Kim, J. H.
    Choi, T. K.
    Lee, S. H.
    Kim, M. K.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S701 - S702
  • [32] Comparative cost-effectiveness of amisulpride and olanzapine in the treatment of schizophrenia in China
    Yi, Zhan-Miao
    Men, Peng
    Qu, Shuli
    Li, Chaoyun
    Yu, Xin
    Zhai, Suodi
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2020, 20 (03) : 313 - 320
  • [33] Treatment resistant schizophrenia, residual subtype: Symptom improvement after additional treatment with amisulpride
    Wolf, K
    Veismann, S
    Knecht, G
    Naber, D
    PSYCHIATRISCHE PRAXIS, 2006, 33 (01) : 42 - 44
  • [34] Amisulpride treatment of adolescent patients with schizophrenia or schizo-affective disorders
    Fatma Varol Tas
    Taner Guvenir
    European Child & Adolescent Psychiatry, 2009, 18 : 511 - 513
  • [35] Clinical update on amisulpride in deficit schizophrenia
    Rein, W
    Turjanski, S
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1997, 12 : S19 - S27
  • [36] Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia
    Loo, H
    PoirierLittre, MF
    Theron, M
    Rein, W
    Fleurot, O
    BRITISH JOURNAL OF PSYCHIATRY, 1997, 170 : 18 - 22
  • [37] Specific mechanism of action of amisulpride in the treatment of schizophrenia and correlation with clinical response and tolerability
    Juruena, Mario F.
    Ponde de Sena, Eduardo
    Reis de Oliveira, Irismar
    JOURNAL OF RECEPTOR LIGAND AND CHANNEL RESEARCH, 2011, 4 : 49 - 55
  • [38] Amisulpride for the treatment of very-late-onset schizophrenia-like psychosis
    Psarros, Constantin
    Theleritis, Christos G.
    Paparrigopoulos, Thomas J.
    Politis, Antonios M.
    Papadimitriou, George N.
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2009, 24 (05) : 518 - 522
  • [39] Amisulpride: A safe and effective option for the long-term treatment of patients with schizophrenia
    Naber, D
    Arlt, J
    Lambert, M
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2003, 7 (03) : 167 - 175
  • [40] Amisulpride Augmentation of Clozapine in Refractory Schizophrenia
    Chiu, Hsiu-Wen
    Ku, Yu-Chi
    Li, Tien-Chun
    Huang, Hsin-Te
    JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, 2011, 23 (03) : E15 - E15